According to filings with the U.S. Securities and Exchange Commission, Protogenix is raising up to $4,200,000.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Protogenix
Protogenix is a developer of a platform technology designed to replace the Mammalian Cell System for manufacturing complex proteins and eliminate the carbon footprint of animal agriculture. The company offers a decentralized, plug-and-play method that delivers high-yield production at higher speed and lower cost than existing methods, enabling food and pharmaceutical producers to access sustainably produced, safe protein ingredients.

To learn more about Protogenix, visit https://www.proto-genix.com/
Protogenix Linkedin Page: https://www.linkedin.com/company/protogenix-inc/

Contact:
Philippe Funfrock, Chief Executive Officer
607-592-8781
https://www.linkedin.com/in/philippe-funfrock/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.